Special Issue

Lithium in Psychiatric Therapy: Celebrating 75th Anniversary

Message from the Guest Editors

This Special Issue celebrates the 75th anniversary of introducing lithium into modern psychiatry, hallmarked by a seminal publication of John Cade in the *Medical* Journal of Australia in 1949. In such vein, we call for papers (especially review papers) demonstrating how. after three-quarters of a century, lithium has been consolidated as one of the most important drugs in psychiatry nowadays. Therefore, historical accounts showing developments in the lithium treatment of mania, depression (including the augmentation of antidepressant drugs), and lithium prophylaxis for mood disorders are welcome. The chronicle tales of the antisuicidal, immunomodulatory, antiviral, and neuroprotective (antidementia) effects of lithium are invited. The papers in this Special Issue may cover a number of areas, such as the expansion of genetic studies on lithium, fluctuating views on the adverse effects of this ion (e.g., on kidney and thyroid function), or the use of lithium in pregnancy. Any other developmental stories about lithium over the past 75 years (e.g., a history of IGSLI) are welcome.

Guest Editors

Prof. Dr. Janusz K. Rybakowski

Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland

Dr. Ewa Ferensztajn-Rochowiak

Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland

Deadline for manuscript submissions

closed (25 November 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/202855

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

